Home » Stocks » AMEH

Apollo Medical Holdings, Inc. (AMEH)

Stock Price: $21.67 USD -0.04 (-0.18%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 783.26M
Revenue (ttm) 689.15M
Net Income (ttm) 34.54M
Shares Out 53.51M
EPS (ttm) 0.96
PE Ratio 22.55
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $21.67
Previous Close $21.71
Change ($) -0.04
Change (%) -0.18%
Day's Open 21.45
Day's Range 21.22 - 21.99
Day's Volume 48,538
52-Week Range 9.55 - 21.99


Hide News
Zacks Investment Research - 1 week ago

We recommend a few lesser-known stocks that hold promise for high returns this year. ADTN, AMEH, ATEC, DFIN and DGII fit the bill.

Other stocks mentioned: ADTN, ATEC, DFIN, DGII
Zacks Investment Research - 4 weeks ago

The COVID-19 crisis has drastically transformed the fortune of the medical services industry. The industry has been witnessingsignificant demand for telemedicine-focused online medical services.

Other stocks mentioned: CDNA, HROW, BMXMF

About AMEH

Apollo Medical Holdings, a physician-centric technology-powered healthcare management company, provides medical care services. The company, leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver quality care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and hea... [Read more...]

Medical Care Facilities
Dr. Kenneth T. Sim M.D.
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2019, AMEH's revenue was $560.62 million, an increase of 7.83% compared to the previous year's $519.91 million. Earnings were $14.12 million, an increase of 30.29%.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for AMEH stock is "Buy" and the 12-month stock price forecast is 30.00.

Price Target
Analyst Consensus: Buy